Research
Eldercare robot helps people sit and stand, and catches them if they fall
To help address the eldercare challenge, a team of MIT engineers is looking to robotics. They have built and tested the Elderly Bodily Assistance Robot, or E-BAR, a mobile robot designed to physically support the elderly and prevent them from falling as they move around their homes.
The United States population is older than it has ever been. Today, the country’s median age is 38.9, which is nearly a decade older than it was in 1980. And the number of adults older than 65 is expected to balloon from 58 million to 82 million by 2050.
The challenge of caring for the elderly, amid shortages in care workers, rising health care costs, and evolving family structures, is an increasingly urgent societal issue.
E-BAR
E-BAR acts as a set of robotic handlebars that follows a person from behind. A user can walk independently or lean on the robot’s arms for support. The robot can support the person’s full weight, lifting them from sitting to standing and vice versa along a natural trajectory. And the arms of the robot can them by rapidly inflating side airbags if they begin to fall.
With their design, the researchers hope to prevent falls, which today are the leading cause of injury in adults who are 65 and older.
“Many older adults underestimate the risk of fall and refuse to use physical aids, which are cumbersome, while others overestimate the risk and may not to exercise, leading to declining mobility,” said Harry Asada, the Ford Professor of Engineering at MIT.
“Our design concept is to provide older adults having balance impairment with robotic handlebars for stabilising their body. The handlebars go anywhere and provide support anytime, whenever they need.”
In its current version, the robot is operated via remote control. In future iterations, the team plans to automate much of the bot’s functionality, enabling it to autonomously follow and physically assist a user.
The researchers are also working on streamlining the device to make it slimmer and more manoeuvrable in small spaces.
“I think eldercare is the next great challenge,” says E-BAR designer Roberto Bolli, a graduate student in the MIT Department of Mechanical Engineering.
“All the demographic trends point to a shortage of caregivers, a surplus of elderly persons, and a strong desire for elderly persons to age in place. We see it as an unexplored frontier in America, but also an intrinsically interesting challenge for robotics.”
Bolli and Asada will present a paper detailing the design of E-BAR at the IEEE Conference on Robotics and Automation (ICRA) later this month.
Home support
Asada’s group at MIT develops a variety of technologies and robotic aides to assist the elderly. In recent years, others have developed fall prediction algorithms, designed robots and automated devices including robotic walkers, wearable, self-inflating airbags, and robotic frames that secure a person with a harness and move with them as they walk.
In designing E-BAR, Asada and Bolli aimed for a robot that essentially does three tasks: providing physical support, preventing falls, and safely and unobtrusively moving with a person. What’s more, they looked to do away with any harness, to give a user more independence and mobility.
“Elderly people overwhelmingly do not like to wear harnesses or assistive devices,” Bolli said.
“The idea behind the E-BAR structure is, it provides body weight support, active assistance with gait, and fall catching while also being completely unobstructed in the front. You can just get out anytime.”
The team looked to design a robot specifically for ageing in place at home or helping in care facilities. Based on their interviews with older adults and their caregivers, they came up with several design requirements, including that the robot must fit through home doors, allow the user to take a full stride, and support their full weight to help with balance, posture, and transitions from sitting to standing.
The robot consists of a heavy, 220-pound base whose dimensions and structure were optimised to support the weight of an average human without tipping or slipping.
Underneath the base is a set of omnidirectional wheels that allows the robot to move in any direction without pivoting, if needed. (Imagine a car’s wheels shifting to slide into a space between two other cars, without parallel parking.)
Extending out from the robot’s base is an articulated body made from 18 interconnected bars, or linkages, that can reconfigure like a foldable crane to lift a person from a sitting to standing position, and vice versa.
Two arms with handlebars stretch out from the robot in a U-shape, which a person can stand between and lean against if they need additional support. Finally, each arm of the robot is embedded with airbags made from a soft yet grippable material that can inflate instantly to catch a person if they fall, without causing bruising on impact.
The researchers believe that E-BAR is the first robot able to catch a falling person without wearable devices or use of a harness.
They tested the robot in the lab with an older adult who volunteered to use the robot in various household scenarios. The team found that E-BAR could actively support the person as they bent down to pick something up from the ground and stretched up to reach an object off a shelf – tasks that can be challenging to do while maintaining balance.
The robot also was able to lift the person up and over the lip of a tub, simulating the task of getting out of a bathtub.
Bolli envisions a design like E-BAR would be ideal for use in the home by elderly people who still have a moderate degree of muscle strength but require assistive devices for activities of daily living.
“Seeing the technology used in real-life scenarios is really exciting,” said Bolli.
In their current paper, the researchers did not incorporate any fall-prediction capabilities in E-BAR’s airbag system. But another project in Asada’s lab, led by graduate student Emily Kamienski, has focused on developing algorithms with machine learning to control a new robot in response to the user’s real-time fall risk level.
Alongside E-BAR, Asada sees different technologies in his lab as providing different levels of assistance for people at certain phases of life or mobility.
“Eldercare conditions can change every few weeks or months,” Asada said. “We’d like to provide continuous and seamless support as a person’s disability or mobility changes with age.”
This work was supported, in part, by the National Robotics Initiative and the National Science Foundation.
NICE will review whether new Alzheimer’s drugs should be offered on the NHS after an appeal found their wider impact was not fully counted.
An appeal found that the National Institute for Health and Care Excellence had failed to properly account for the wider impact of the treatments, including the heavy burden on unpaid carers, when calculating the cost effectiveness of the medicines.
Both treatments, lecanemab and donanemab, will now return to a NICE committee for further consideration.
“Today’s ruling is an opportunity for NICE to consider the real cost of Alzheimer’s on people and their families, and we welcome the decision to look again at whether new medicines could be provided on the NHS,” said David Thomas, head of policy and public affairs at Alzheimer’s Research UK.
Lecanemab and donanemab do not cure Alzheimer’s, but they slow it by targeting and clearing clumps of amyloid proteins, sticky protein build-ups in the brain linked to the disease.
While the drugs are available privately in the UK for people who can afford them, NICE ruled last year that they were too expensive to be made available on the NHS in England and Wales.
It is estimated informal dementia care costs the economy more than £20bn a year.
Alzheimer’s Research UK wants NICE to update how it assesses the value of new dementia drugs and factor in the huge additional costs this condition places on society and the wider economy.
NICE and its expert committees assess whether new drugs are good value for money for the NHS based on a wide range of evidence.
This includes how treatments perform in clinical trials, the experiences of patients and carers, and the costs of new drugs as well as any changes to NHS services needed to provide access.
When NICE weighs up whether a new Alzheimer’s drug is cost effective for the NHS, it carries out a limited assessment of the impact dementia has on the health of carers.
But the condition takes an enormous toll on families and society because caring for someone with dementia can lead people to become more isolated and give up work.
It can have a major emotional impact and put families under financial strain.
Thomas said: “Research has delivered new treatments with the potential to provide people with valuable extra months of independence, lessening the burden on carers.
“While these treatments offer modest benefits and can cause serious side effects, they provide the foundation for a future where dementia becomes a treatable condition.
“Now we need NICE to look again at how these medicines could benefit both people with early Alzheimer’s and their carers.”
Chris, whose mother Shirley is living with Alzheimer’s disease, said: “The real cost of Alzheimer’s is far greater than many people realise.
“In order to give my mum the care she needed, I moved back home to help my dad as the care was too much for him alone. After my dad passed away from Covid in 2021, I became sole carer for my mum.
“It was a very difficult period, working a full-time job, caring for Mum and dealing with the loss of my dad. Eventually I got some in-home care support to help.
“The family has borne most of the cost of Mum’s care, both in time and fees, and the family home has been sold to finance it.”
“The emotional and financial strain Alzheimer’s has taken on our family is horrendous, and I know many families across the UK are experiencing this pressure.”
He is backing Alzheimer’s Research UK’s call for NICE to change how it evaluates new dementia treatments.
The timeframe for the next NICE meetings to discuss the drugs is still to be set, and it is not certain follow-up hearings would change NICE’s guidance on access to the medicines.
But Alzheimer’s Research UK is continuing to push to make sure dementia is now a main priority for political and NHS decision-makers.
The head of the ongoing independent review into adult social care, Baroness Louise Casey, has called on the government to act, show leadership and prioritise dementia.
She has proposed appointing a dementia tsar to drive forward the prevention, treatment and care of dementia.
Baroness Casey has also argued for more funding for dementia treatment trials.
With more than 130 Alzheimer’s drugs in clinical trials worldwide, the charity says it is vital the NHS runs trials of new treatments now to understand how to deliver them to eligible patients in future.
In addition to changing how NICE assesses new medicines, the health service needs to collect real-world evidence on new dementia drugs and prepare for diagnostic tests and innovative treatments that are coming.
“Alzheimer’s Research UK is calling on the government to give dementia the same political determination that transformed cancer care,” Thomas said.
“We urgently need investment and a clear UK-wide plan so new treatments can be assessed in the NHS and reach the people who stand to benefit.”
Health and social care secretary Wes Streeting has said dementia is “one of the greatest challenges of our time” and pledged that the UK should become a world leader in dementia clinical trials.
Osteoporosis drugs may lower dementia risk, with a study suggesting one widely used treatment could help prevent Alzheimer’s and related dementias.
The research found that nitrogen-containing bisphosphonates, drugs widely used to treat osteoporosis, may significantly reduce the risk of Alzheimer’s disease and related dementias in older adults with osteoporosis or fragility fractures.
Osteoporosis and dementia often coexist in older adults and share several risk factors, including advanced age, female sex and reduced physical activity.
Researchers at the University of Hong Kong’s department of pharmacology and pharmacy carried out a large study using the city’s electronic medical records, covering more than 120,000 patients aged 60 and above with osteoporosis or fragility fractures between 2005 and 2020.
The team found that NBP users had a 16 per cent lower risk of developing Alzheimer’s disease and related dementias than untreated patients, and a 24 per cent lower risk than those who received other osteoporosis medicines.
The association was especially marked in women and patients with hip fractures.
The researchers estimated that treating 48 patients with NBPs for five years could potentially prevent one case of dementia, underlining the possible public health value of NBPs in high-risk groups.
Professor Cheung Ching-lung, associate professor in the department of pharmacology and pharmacy at the University of Hong Kong, said: “Our study provides evidence that NBPs may offer dual benefits in strengthening bones and reducing fracture risk, as well as potentially preventing ADRD.
“Their potential neuroprotective role provides an empirical basis and supports future research on the actual effectiveness of this medication in preventing or delaying cognitive decline associated with ADRD.
“These findings are significant as they demonstrate a potential approach for reducing dementia risk in a vulnerable population using safe and widely available NBPs.
“In our rapidly ageing society, these findings suggest that while waiting for the novel therapies, existing medications can also provide additional protection for high-risk populations.”
The same research team has previously found that osteoporosis and fractures are independent risk factors for dementia, and that patients with dementia are at higher risk of falls and fractures.
This suggests treating osteoporosis may also help reduce the burden of dementia.
NBPs, including alendronate and zoledronate, are well established and commonly prescribed osteoporosis drugs.
Emerging biological research suggests the pathways affected by NBPs may also play a role in the development of Alzheimer’s disease and related dementias, raising the possibility that they could be repurposed for prevention.
A prebiotic fibre supplement may ease arthritis pain and improve grip strength in people with knee osteoarthritis, a study suggests.
The daily supplement, made from inulin, a dietary fibre found in chicory root, Jerusalem artichokes and other vegetables, also lowered pain sensitivity and saw fewer people drop out than a digital physiotherapy programme tested alongside it.
Dr Afroditi Kouraki, lead author of the study from the University of Nottingham, said: ‘Our findings suggest that targeting gut health with a prebiotic supplement is a safe, well-tolerated, and effective way to reduce pain in people with knee osteoarthritis.
“The very low dropout rate compared to the exercise group is also encouraging from a public health perspective, people were able to fit this supplement easily into their daily lives.’
Osteoarthritis of the knee, a wear-and-tear joint condition, affects hundreds of millions of people worldwide and is a leading cause of pain and disability, particularly in older adults.
Current treatments rely heavily on pain medication, which can cause side effects, or exercise programmes, which many patients find hard to maintain.
The INSPIRE trial, led by researchers at the University of Nottingham, involved 117 adults with knee osteoarthritis and tested four groups: inulin alone, digital physiotherapy-supported exercise alone, a combination of both, and a placebo. Both inulin and physiotherapy independently reduced knee pain.
However, inulin alone improved grip strength and reduced pain sensitivity, measures linked to how the nervous system processes pain, while physiotherapy did not.
The dropout rate for those taking the supplement was just 3.6 per cent, compared with 21 per cent for the physiotherapy group, suggesting a daily supplement may be easier for people to stick with than an exercise programme.
Inulin works as a prebiotic, meaning it feeds beneficial bacteria in the gut.
This leads to the production of compounds called short-chain fatty acids, particularly butyrate, which can affect inflammation and pain pathways throughout the body.
Participants taking inulin also showed increased levels of both butyrate and GLP-1, a gut hormone linked to pain regulation and muscle health.
Higher GLP-1 levels were associated with improved grip strength, pointing to a possible gut-muscle connection.
Senior author Professor Ana Valdes added: ‘The link we observed between GLP-1 and grip strength is particularly intriguing and points to a broader gut-muscle-pain axis that warrants further investigation. This could have implications not just for osteoarthritis, but for understanding how gut health influences ageing and physical resilience more broadly.’
Professor Lucy Donaldson, director of research at Arthritis UK, said: “The pain of arthritis can severely impact quality of life. Our recent lived experience survey showed that six in ten people are living in pain most or all of the time due to their arthritis.
“Researchers are starting to explore the role of the gut microbiome in our experience of pain.
“This exciting preliminary research highlights how diet and physiotherapy can act in different ways to have benefits for people with arthritis.
“We know a variety and balance of healthy foods, including fibre, and regular physical activity matter, and we’re glad to be supporting research that explores how they work to help people with arthritis.”
Gut-friendly foods may damage heart, charity warns
Diabetes patients face increased risk of undiagnosed heart failure
UK government announces £6.3m fund to boost men’s health
Brain health collaboratory launches in Gulf South
